In recent decades, one of the major breakthroughs in cancer immunotherapy has been the discovery of immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1) and its ligand [programmed death-ligand 1 (PD-L1)]. Here, CD274 is linked to cancer.